MorphoSys
MorphoSys AG, a leading biopharmaceutical company headquartered in Germany, is renowned for its innovative approach in the field of therapeutic antibodies. Founded in 1992, the company has made significant strides in the development of treatments for cancer and autoimmune diseases, establishing a strong presence in Europe and North America.
With a focus on proprietary and partnered drug development, MorphoSys has achieved notable milestones, including the successful launch of its flagship product, Monjuvi (tafasitamab), which targets specific forms of lymphoma. The company’s unique technology platforms, such as its Ylanthus® antibody library, enable the rapid discovery of high-quality therapeutic candidates, positioning MorphoSys as a key player in the biopharmaceutical industry. Through its commitment to advancing healthcare, MorphoSys continues to make impactful contributions to patient care and treatment options.
+61 vs industry average
MorphoSys’s score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at MorphoSys?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Emissions trajectory 2020 – 2028
Reported emissions
Scope 3 accounts for ••• of total emissions.
MorphoSys's reported carbon emissions
In 2025, MorphoSys reported total carbon emissions of approximately 34.5 million kg CO2e. This figure includes Scope 1 emissions of about 964,000 kg CO2e, Scope 2 emissions of approximately 88,000 kg CO2e (market-based), and a significant contribution from Scope 3 emissions, which totalled around 33.4 million kg CO2e. The largest components of Scope 3 emissions were from purchased goods and services, accounting for about 26.6 million kg CO2e.
In 2024, the company’s total emissions were approximately 49.3 million kg CO2e, with Scope 1 emissions at about 1,053,000 kg CO2e, Scope 2 emissions at approximately 114,000 kg CO2e (market-based), and Scope 3 emissions reaching around 48.1 million kg CO2e. Again, purchased goods and services were the primary contributor to Scope 3 emissions.
For 2023, MorphoSys reported total emissions of approximately 18.9 million kg CO2e, with Scope 1 emissions of about 101,820 kg CO2e, Scope 2 emissions of approximately 1,340 kg CO2e (market-based), and Scope 3 emissions at around 18.8 million kg CO2e.
MorphoSys has not set specific reduction targets or initiatives as per the available data. The company is part of a corporate family relationship with Novartis AG, which influences its climate commitments and reporting. Emissions data and climate initiatives may be cascaded from Novartis AG, reflecting a broader commitment to sustainability within the merged entity framework.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
MorphoSys’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for MorphoSys yet.
Scope 3 top emissions categories
11 of 15 categories disclosedSee all scope 3 categories
Already have an account? Sign in now
Emissions comparison with industry peers
View similar organisations
MorphoSys
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project